Opthea

Opthea is dedicated to enhancing vision in individuals afflicted with retinal eye conditions. We are in the process of creating a new treatment known as OPT-302, a VEGF-C/D 'trap', designed to be utilized alongside current standard anti-VEGF-A therapies. OPT-302 holds promise in addressing the unsatisfied medical requirement of wet AMD and DME patients, a significant portion of whom do not respond adequately or develop resistance to existing treatments for these incapacitating illnesses. Progress is being made in the clinical advancement of OPT-302 through Phase 2 trials for wet AMD and DME.